Valuation: Dermapharm Holding SE

Market Cap 189.25Cr 210.93Cr 174.97Cr 158.46Cr 296.05Cr 20TCr 299.63Cr 2.09TCr 833.23Cr 11TCr 791.53Cr 774.83Cr 33TCr P/E 2026 *
14.6x
P/E 2027 * 12.9x
Enterprise Value 270.42Cr 301.4Cr 250.01Cr 226.43Cr 423.03Cr 29TCr 428.14Cr 2.99TCr 1.19TCr 15TCr 1.13TCr 1.11TCr 48TCr EV / Sales 2026 *
2.24x
EV / Sales 2027 * 2.06x
Free-Float
10.7%
Yield 2026 *
2.67%
Yield 2027 * 2.98%
1 day-0.52%
1 week-1.55%
Current month-2.55%
1 month-2.92%
3 months-8.50%
6 months-16.50%
Current year-2.92%
1 week 37.8
Extreme 37.8
38.95
1 month 37.35
Extreme 37.35
39.7
Current year 34.3
Extreme 34.3
51.9
1 year 32.9
Extreme 32.9
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Buy

Chairman

3,80,000 0.7670%
07/01/26 Buy 150 0.0003%
07/01/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-1.55%+17.54%+3.41% 211.96Cr
+0.50%+1.38%+57.09%+129.96% 1,14300Cr
+0.86%+5.14%+45.00%+86.15% 65TCr
-0.14%+0.42%+25.69%+105.85% 51TCr
-0.05%+1.73%+52.74%+67.74% 38TCr
-0.63%-5.97%+61.93%+37.06% 35TCr
+0.34%+1.84%+30.70%+54.27% 29TCr
-0.45%+1.19%+2.89%+26.08% 26TCr
+0.87%+3.08%+54.69%+72.74% 24TCr
+0.08%+3.67%+35.05%+107.78% 20TCr
Average +0.09%+0.80%+38.33%+69.10% 40.3TCr
Weighted average by Cap. +0.25%+0.71%+44.48%+88.97%

Financials

2026 *2027 *
Net sales 120.86Cr 134.7Cr 111.74Cr 101.2Cr 189.06Cr 13TCr 191.35Cr 1.34TCr 532.12Cr 6.71TCr 505.49Cr 494.82Cr 21TCr 125.45Cr 139.82Cr 115.98Cr 105.04Cr 196.24Cr 13TCr 198.61Cr 1.39TCr 552.33Cr 6.97TCr 524.69Cr 513.61Cr 22TCr
Net income 14Cr 15Cr 13Cr 11Cr 21Cr 1.46TCr 22Cr 151.72Cr 60Cr 762.41Cr 57Cr 56Cr 2.42TCr 16Cr 17Cr 14Cr 13Cr 24Cr 1.65TCr 25Cr 171.7Cr 68Cr 862.82Cr 65Cr 64Cr 2.74TCr
Net Debt 81Cr 90Cr 75Cr 68Cr 126.98Cr 8.62TCr 128.52Cr 897.3Cr 357.4Cr 4.51TCr 339.51Cr 332.35Cr 14TCr 69Cr 77Cr 64Cr 58Cr 107.45Cr 7.29TCr 108.75Cr 759.28Cr 302.42Cr 3.82TCr 287.29Cr 281.23Cr 12TCr
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
28/26/28 €38.20 -0.52% 15,757
27/26/27 €38.40 +1.45% 11,217
26/26/26 €37.85 -1.43% 10,131
23/26/23 €38.40 -0.78% 18,324
22/26/22 €38.70 -0.26% 9,838
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.20EUR
Average target price
51.00EUR
Spread / Average Target
+33.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE